Association between P53 Gene Mutations and Colorectal Cancer in the Iranian Population: A Systematic Review
-
Nima Nikbin Kavishahi
,
Javad Yaghmoorian Khojini
,
Mehrazin Khamespanah Duruh
,
Benjamin Babaei
,
Mohammad Hasan Sheikhha
Abstract
Background: Colorectal cancer (CRC) is the fourth most common cancer and one of the most significant cancers affecting the Iranian population. This systematic review aimed to investigate the association between mutations in the P53 gene and CRC.
Methods: We conducted a search of six databases, including; Scopus, PubMed, Web of Science, Cochrane Library, SID, and Magiran up to Aug 10, 2024. Concepts in the search strategy were Iran, P53, and "Colorectal cancer". Original articles written in English or Persian that investigated the association between P53 gene mutations and CRC in the Iranian population were included.
Results: Out of 313 articles, 17 articles were included in the study. Six case-control studies investigated the association between the codon 72 polymorphism of the P53 gene and colorectal cancer. Three studies found a significant difference in genotype frequencies of this polymorphism between CRC patients and healthy individuals. Exon 6 was shown to be one of the most common mutated exons in colorectal cancer. Mutations in exon 7 were associated with poor prognosis. The most common type of mutation was G to A mutation from exons 5 to 8 CpG sites.
Conclusion: The present study suggests a potential association between the presence of the Arg allele at codon 72 within the P53 gene and a heightened susceptibility for developing and metastasizing CRC within the Iranian population. Furthermore, exons 5 to 8 of the P53 gene suggests that mutations localized at these sites may portend a poor prognosis.
1. Shadmani FK, Ayubi E, Khazaei S, et al (2017). Geographic distribution of the incidence of colorectal cancer in Iran: a population-based study. Epidemiol Health, 39:e2017020.
2. Onyoh EF, Hsu WF, Chang LC, et al (2019). The Rise of Colorectal Cancer in Asia: Epidemiology, Screening, and Management. Curr Gastroenterol Rep, 21 (8):36.
3. Ganji A SM, Nouraie S, Nasseri-Moghadam S, et al (2006). Digestive and liver diseases statistics in several referral centers in Tehran, 2000-2004. Govaresh, 11:33-58.
4. AziziKia H, Teymourzadeh A, Kouchaki H, et al (2024). Colorectal Cancer Incidence in Iran Based on Sex, Age, and Geographical Regions: A Study of 2014–2017 and Projected Rates to 2025. Arch Iran Med, 27 (4):174-182.
5. Cottu PH, Muzeau F, Estreicher A, et al (1996). Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines. Oncogene, 13 (12):2727-30.
6. Szvicsek Z, Oszvald Á, Szabó L, et al (2019). Extracellular vesicle release from intestinal organoids is modulated by Apc mutation and other colorectal cancer progression factors. Cell Mol Life Sci, 76:2463-2476.
7. Meng M, Zhong K, Jiang T, et al (2021). The current understanding on the impact of KRAS on colorectal cancer. Biomed Pharmacother, 140:111717.
8. Jancík S, Drábek J, Radzioch D, et al (2010). Clinical relevance of KRAS in human cancers. J Biomed Biotechnol, 2010:150960.
9. Shingu T, Holmes L, Henry V, et al (2016). Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. J Transl Med, 14:46.
10. Van Schaeybroeck S, Kalimutho M, Dunne PD, et al (2014). ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. Cell Rep, 7 (6):1940-55.
11. Ryan KM, Phillips AC, Vousden KH (2001). Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol, 13 (3):332-7.
12. Russo A, Bazan V, Iacopetta B, et al (2005). The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol, 23 (30):7518-28.
13. Kandoth C, McLellan MD, Vandin F, et al (2013). Mutational landscape and significance across 12 major cancer types. Nature, 502 (7471):333-339.
14. López I, L PO, Tucci P, et al (2012). Different mutation profiles associated to P53 accumulation in colorectal cancer. Gene, 499 (1):81-7.
15. Baugh EH, Ke H, Levine AJ, et al (2018). Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ, 25 (1):154-160.
16. Iacopetta B (2003). TP53 mutation in colorectal cancer. Hum Mutat, 21 (3):271-6.
17. Ahnen DJ, Feigl P, Quan G, et al (1998). Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res, 58 (6):1149-58.
18. Elsaleh H, Powell B, McCaul K, et al (2001). P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res, 7 (5):1343-9.
19. Liang JT, Huang KC, Cheng YM, et al (2002). P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. Int J Cancer, 97 (4):451-7.
20. Bunz F, Hwang PM, Torrance C, et al (1999). Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest, 104 (3):263-9.
21. Mojtahedi Z, Haghshenas MR, Hosseini SV, et al (2010). P 53 codon 72 polymorphism in stomach and colorectal adenocarcinomas in Iranian patients. Indian J Cancer, 47 (1):31-34.
22. Pignatelli M, Stamp G, Kafiri G, et al (1992). Over-expression of p53 nuclear oncoprotein in colorectal adenomas. Int J Cancer, 50 (5):683-688.
23. Page MJ, McKenzie JE, Bossuyt PM, et al (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 372:n71.
24. Dastjerdi MN, Salehi M, Mohajeri MR, et al (2008). Evidence for an association of TP53 codon 72 polymorphism with sporadic colorectal cancer risk in Isfahan. Journal of Research in Medical Sciences, 13 (6):317-323.
25. Dastjerdi MN (2011). TP53 codon 72 polymorphism and P53 protein expression in colorectal cancer specimens in Isfahan. Acta Med Iran, 49 (2):71-77.
26. Doosti A, Ghasemi Dehkordi P, Zamani M, et al (2011). Association of the p53 codon 72 polymorphism with colorectal cancer in south west of Iran. World Academy of Science, Engineering and Technology, 74:117-120.
27. Faghani M, Fakhrieh S (2012). Evaluation of p53 codon 72 polymorphism in adenocarcinoma of the colon and rectum in Guilan province. Govaresh, 17 (1):25-32.
28. Asadi M, Shanehbandi D, Zarintan A, et al (2017). TP53 Gene Pro72Arg (rs1042522) single nucleotide polymorphism as not a risk factor for colorectal cancer in the Iranian Azari population. Asian Pac J Cancer Prev, 18 (12):3423-3427.
29. Dastjerdi MN, Sadeghi HM (2010). TP53 Codon 72 Heterozygosity May Promote MicrosatelliteInstability in Sporadic Colorectal Cancer. Cell Journal (Yakhteh), 12 (1):25-32.
30. Dastjerdi MN (2010). Analysis of TP53 codon 72 polymorphism in mucinous and non-mucinous colorectal adenocarcinoma in Isfahan, Iran. Iranian Journal of Medical Sciences, 35 (1):33-39.
31. Golmohammadi R, Nikbakht M (2007). Assessment the relationship between p53 exon 6 mutations with protein over expression and prognosis in colorectal cancer by immuno histochemistry and sscp. Journal of Sabzevar University of Medical Sciences, 13 (1):7.
32. Golmohamadi R, Nikbakht M, Salehi M, et al (2007). Detection of P53 exon 6 mutions in colorectal cancer patients by PCR-SSCP method in Isfahan Hospital during 2004 -2005. Feyz, 10 (2):1-.
33. Golmohammadi R, Nikbakht M (2009). Frequency of the correlation between mutation in 7th exon of p53 gene and the prognosis of colorectal cancer. Journal of Kermanshah University of Medical Sciences (Behbood), 12 (4 (39)):-.
34. Lohrasbi Nejad A, Yaghoobi Mm (2012). Mutation analysis oftp53 tumor suppressor gene in colorectal cancer in patients from iran (kerman province). Iran J Basic Med Sci, 15 (1):683-90.
35. Mahdavinia M, Bishehsari F, Verginelli F, et al (2008). P53 mutations in colorectal cancer from Northern Iran: Relationships with site of tumor origin, microsatellite instability and K-ras mutations. J Cell Physiol, 216 (2):543-550.
36. Golmohammadi R, Nikbakhat M, Salehi M (2008). Mutations in Exons 7 and 8 of P53 Gene in Colorectal Cancer and Their Association with Histopathologic Parameters and Anatomic Locations of the Tumor. Govaresh, 12 (4):244-248.
37. Golmohammadi R, Namazi MJ, Nikbakht M, et al (2013). Characterization and prognostic value of mutations in exons 5 and 6 of the p53 gene in patients with colorectal cancers in central Iran. Gut Liver, 7 (3):295-302.
38. Dayemomid S, Narjabadifam M, Behrouz Sharif S, et al (2022). Detection of Mutations in Exons 5, 6, and 7 of the TP53 Gene in the Tumor Tissue and Stool Samples of Patients with Colorectal Cancer from Northwest Iran. Middle East J Cancer, 13 (1):34-42.
39. Ashktorab H, Mokarram P, Azimi H, et al (2017). Targeted exome sequencing reveals distinct pathogenic variants in iranians with colorectal cancer. Oncotarget, 8 (5):7852-7866.
40. Pérez LO, Abba MC, Dulout FN, et al (2006). Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol, 12 (9):1426-9.
41. Mammano E, Belluco C, Bonafe M, et al (2009). Association of p53 polymorphisms and colorectal cancer: modulation of risk and progression. Eur J Surg Oncol, 35 (4):415-419.
42. Gemignani F, Moreno V, Landi S, et al (2004). A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene, 23 (10):1954-1956.
43. Lung F-W, Lee T-M, Shu B-C, et al (2004). p53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan. J Cancer Res Clin Oncol, 130 (12):728-32.
44. Zhu ZZ, Wang AZ, Jia HR, et al (2007). Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol, 37 (5):385-90.
45. Tabatabaei SH, Sheikhha MH, Karbasi MHA, et al (2018). Evaluation of polymorphism of P53 protein codon 72 in oral lichen planus by PCR technique. J Dent Res Dent Clin Dent Prospects, 12 (4):245-251.
46. Dumont P, Leu JI, Della Pietra AC, et al (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet, 33 (3):357-65.
47. Thomas M, Kalita A, Labrecque S, et al (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol, 19 (2):1092-100.
48. Sobczuk A, Romanowicz-Makowska H, Smolarz B, et al (2007). Microsatellite instability (MSI) and MLH1 and MSH2 protein expression analysis in postmenopausal women with sporadic endometrial cancer. J Exp Clin Cancer Res, 26 (3):369-74.
49. Lee S, Elenbaas B, Levine A, et al (1995). p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell, 81 (7):1013-20.
50. Furihata M, Takeuchi T, Matsumoto M, et al (2002). p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract. Clin Cancer Res, 8 (5):1192-5.
51. Ozer E, Yuksel E, Kizildag S, et al (2002). Microsatellite instability in early-onset breast cancer. Pathol Res Pract, 198 (8):525-30.
52. Stoler DL, Datta RV, Charles MA, et al (2002). Genomic instability measurement in the diagnosis of thyroid neoplasms. Head Neck, 24 (3):290-5.
53. Burger M, Burger SJ, Denzinger S, et al (2006). Elevated microsatellite instability at selected tetranucleotide repeats does not correlate with clinicopathologic features of bladder cancer. Eur Urol, 50 (4):770-5.
54. Saetta AA, Gigelou F, Papanastasiou PI, et al (2006). High-level microsatellite instability is not involved in gallbladder carcinogenesis. Exp Mol Pathol, 80 (1):67-71.
55. Roa JC, Roa I, Melo A, et al (2000). [p53 gene mutation in cancer of the colon and rectum]. Rev Med Chil, 128 (9):996-1004.
56. Leahy DT, Salman R, Mulcahy H, et al (1996). Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis. J Pathol, 180 (4):364-70.
57. Yamashita K, Yoshida T, Shinoda H, et al (2001). Novel method for simultaneous analysis of p53 and K-ras mutations and p53 protein expression in single histologic sections. Arch Pathol Lab Med, 125 (3):347-52.
58. Pan ZZ, Wan DS, Chen G, et al (2004). Co-mutation of p53, K-ras genes and accumulation of p53 protein and its correlation to clinicopathological features in rectal cancer. World J Gastroenterol, 10 (24):3688-90.
59. Iniesta P, Vega FJ, Caldés T, et al (1998). p53 exon 7 mutations as a predictor of poor prognosis in patients with colorectal cancer. Cancer Lett, 130 (1-2):153-60.
60. Cristi E, Perrone G, Toscano G, et al (2005). Tumour proliferation, angiogenesis, and ploidy status in human colon cancer. J Clin Pathol, 58 (11):1170-4.
61. Perrone G, Vincenzi B, Santini D, et al (2004). Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinico-pathological features in colon cancer. Cancer Lett, 208 (2):227-234.
62. Angelopoulou K, Levesque MA, Katsaros D, et al (1998). Exon 5 of the p53 gene is a target for deletions in ovarian cancer. Clin Chem, 44 (1):72-7.
63. Tseng JE, Rodriguez M, Ro J, Liu D, et al (1999). Gender differences in p53 mutational status in small cell lung cancer. Cancer Res, 59 (22):5666-70.
64. Baumbusch LO, Myhre S, Langerød A, et al (2006). Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters. Mol Cancer, 5:47.
65. Webley KM, Shorthouse AJ, Royds JA (2000). Effect of mutation and conformation on the function of p53 in colorectal cancer. J Pathol, 191 (4):361-7.
66. Soussi T, Béroud C (2003). Significance of TP53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides. Hum Mutat, 21 (3):192-200.
67. Olivier M, Hussain SP, Caron de Fromentel C, et al (2004). TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ, (157):247-70.
68. Chang SC, Lin JK, Yang SH, et al (2006). Relationship between genetic alterations and prognosis in sporadic colorectal cancer. Int J Cancer, 118 (7):1721-7.
69. Molleví DG, Serrano T, Ginestà MM, et al (2007). Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection. Carcinogenesis, 28 (6):1241-6.
70. Lim SC, Lee TB, Choi CH, et al (2008). Prognostic significance of cyclooxygenase-2 expression and nuclear p53 accumulation in patients with colorectal cancer. J Surg Oncol, 97 (1):51-6.
71. Theodoropoulos GE, Karafoka E, Papailiou JG, et al (2009). P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up. Anticancer Res, 29 (2):785-91.
72. Eguchi S, Kohara N, Komuta K, et al (1996). Mutations of the p53 gene in the stool of patients with resectable colorectal cancer. Cancer, 77 (8 Suppl):1707-10.
73. Goshayeshi L, Pourahmadi A, Ghayour-Mobarhan M, et al (2019). Colorectal cancer risk factors in north-eastern Iran: A retrospective cross-sectional study based on geographical information systems, spatial autocorrelation and regression analysis. Geospat Health, 14 (2): 10.4081/gh.2019.793.
2. Onyoh EF, Hsu WF, Chang LC, et al (2019). The Rise of Colorectal Cancer in Asia: Epidemiology, Screening, and Management. Curr Gastroenterol Rep, 21 (8):36.
3. Ganji A SM, Nouraie S, Nasseri-Moghadam S, et al (2006). Digestive and liver diseases statistics in several referral centers in Tehran, 2000-2004. Govaresh, 11:33-58.
4. AziziKia H, Teymourzadeh A, Kouchaki H, et al (2024). Colorectal Cancer Incidence in Iran Based on Sex, Age, and Geographical Regions: A Study of 2014–2017 and Projected Rates to 2025. Arch Iran Med, 27 (4):174-182.
5. Cottu PH, Muzeau F, Estreicher A, et al (1996). Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines. Oncogene, 13 (12):2727-30.
6. Szvicsek Z, Oszvald Á, Szabó L, et al (2019). Extracellular vesicle release from intestinal organoids is modulated by Apc mutation and other colorectal cancer progression factors. Cell Mol Life Sci, 76:2463-2476.
7. Meng M, Zhong K, Jiang T, et al (2021). The current understanding on the impact of KRAS on colorectal cancer. Biomed Pharmacother, 140:111717.
8. Jancík S, Drábek J, Radzioch D, et al (2010). Clinical relevance of KRAS in human cancers. J Biomed Biotechnol, 2010:150960.
9. Shingu T, Holmes L, Henry V, et al (2016). Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. J Transl Med, 14:46.
10. Van Schaeybroeck S, Kalimutho M, Dunne PD, et al (2014). ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. Cell Rep, 7 (6):1940-55.
11. Ryan KM, Phillips AC, Vousden KH (2001). Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol, 13 (3):332-7.
12. Russo A, Bazan V, Iacopetta B, et al (2005). The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol, 23 (30):7518-28.
13. Kandoth C, McLellan MD, Vandin F, et al (2013). Mutational landscape and significance across 12 major cancer types. Nature, 502 (7471):333-339.
14. López I, L PO, Tucci P, et al (2012). Different mutation profiles associated to P53 accumulation in colorectal cancer. Gene, 499 (1):81-7.
15. Baugh EH, Ke H, Levine AJ, et al (2018). Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ, 25 (1):154-160.
16. Iacopetta B (2003). TP53 mutation in colorectal cancer. Hum Mutat, 21 (3):271-6.
17. Ahnen DJ, Feigl P, Quan G, et al (1998). Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res, 58 (6):1149-58.
18. Elsaleh H, Powell B, McCaul K, et al (2001). P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res, 7 (5):1343-9.
19. Liang JT, Huang KC, Cheng YM, et al (2002). P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. Int J Cancer, 97 (4):451-7.
20. Bunz F, Hwang PM, Torrance C, et al (1999). Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest, 104 (3):263-9.
21. Mojtahedi Z, Haghshenas MR, Hosseini SV, et al (2010). P 53 codon 72 polymorphism in stomach and colorectal adenocarcinomas in Iranian patients. Indian J Cancer, 47 (1):31-34.
22. Pignatelli M, Stamp G, Kafiri G, et al (1992). Over-expression of p53 nuclear oncoprotein in colorectal adenomas. Int J Cancer, 50 (5):683-688.
23. Page MJ, McKenzie JE, Bossuyt PM, et al (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 372:n71.
24. Dastjerdi MN, Salehi M, Mohajeri MR, et al (2008). Evidence for an association of TP53 codon 72 polymorphism with sporadic colorectal cancer risk in Isfahan. Journal of Research in Medical Sciences, 13 (6):317-323.
25. Dastjerdi MN (2011). TP53 codon 72 polymorphism and P53 protein expression in colorectal cancer specimens in Isfahan. Acta Med Iran, 49 (2):71-77.
26. Doosti A, Ghasemi Dehkordi P, Zamani M, et al (2011). Association of the p53 codon 72 polymorphism with colorectal cancer in south west of Iran. World Academy of Science, Engineering and Technology, 74:117-120.
27. Faghani M, Fakhrieh S (2012). Evaluation of p53 codon 72 polymorphism in adenocarcinoma of the colon and rectum in Guilan province. Govaresh, 17 (1):25-32.
28. Asadi M, Shanehbandi D, Zarintan A, et al (2017). TP53 Gene Pro72Arg (rs1042522) single nucleotide polymorphism as not a risk factor for colorectal cancer in the Iranian Azari population. Asian Pac J Cancer Prev, 18 (12):3423-3427.
29. Dastjerdi MN, Sadeghi HM (2010). TP53 Codon 72 Heterozygosity May Promote MicrosatelliteInstability in Sporadic Colorectal Cancer. Cell Journal (Yakhteh), 12 (1):25-32.
30. Dastjerdi MN (2010). Analysis of TP53 codon 72 polymorphism in mucinous and non-mucinous colorectal adenocarcinoma in Isfahan, Iran. Iranian Journal of Medical Sciences, 35 (1):33-39.
31. Golmohammadi R, Nikbakht M (2007). Assessment the relationship between p53 exon 6 mutations with protein over expression and prognosis in colorectal cancer by immuno histochemistry and sscp. Journal of Sabzevar University of Medical Sciences, 13 (1):7.
32. Golmohamadi R, Nikbakht M, Salehi M, et al (2007). Detection of P53 exon 6 mutions in colorectal cancer patients by PCR-SSCP method in Isfahan Hospital during 2004 -2005. Feyz, 10 (2):1-.
33. Golmohammadi R, Nikbakht M (2009). Frequency of the correlation between mutation in 7th exon of p53 gene and the prognosis of colorectal cancer. Journal of Kermanshah University of Medical Sciences (Behbood), 12 (4 (39)):-.
34. Lohrasbi Nejad A, Yaghoobi Mm (2012). Mutation analysis oftp53 tumor suppressor gene in colorectal cancer in patients from iran (kerman province). Iran J Basic Med Sci, 15 (1):683-90.
35. Mahdavinia M, Bishehsari F, Verginelli F, et al (2008). P53 mutations in colorectal cancer from Northern Iran: Relationships with site of tumor origin, microsatellite instability and K-ras mutations. J Cell Physiol, 216 (2):543-550.
36. Golmohammadi R, Nikbakhat M, Salehi M (2008). Mutations in Exons 7 and 8 of P53 Gene in Colorectal Cancer and Their Association with Histopathologic Parameters and Anatomic Locations of the Tumor. Govaresh, 12 (4):244-248.
37. Golmohammadi R, Namazi MJ, Nikbakht M, et al (2013). Characterization and prognostic value of mutations in exons 5 and 6 of the p53 gene in patients with colorectal cancers in central Iran. Gut Liver, 7 (3):295-302.
38. Dayemomid S, Narjabadifam M, Behrouz Sharif S, et al (2022). Detection of Mutations in Exons 5, 6, and 7 of the TP53 Gene in the Tumor Tissue and Stool Samples of Patients with Colorectal Cancer from Northwest Iran. Middle East J Cancer, 13 (1):34-42.
39. Ashktorab H, Mokarram P, Azimi H, et al (2017). Targeted exome sequencing reveals distinct pathogenic variants in iranians with colorectal cancer. Oncotarget, 8 (5):7852-7866.
40. Pérez LO, Abba MC, Dulout FN, et al (2006). Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol, 12 (9):1426-9.
41. Mammano E, Belluco C, Bonafe M, et al (2009). Association of p53 polymorphisms and colorectal cancer: modulation of risk and progression. Eur J Surg Oncol, 35 (4):415-419.
42. Gemignani F, Moreno V, Landi S, et al (2004). A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene, 23 (10):1954-1956.
43. Lung F-W, Lee T-M, Shu B-C, et al (2004). p53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan. J Cancer Res Clin Oncol, 130 (12):728-32.
44. Zhu ZZ, Wang AZ, Jia HR, et al (2007). Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol, 37 (5):385-90.
45. Tabatabaei SH, Sheikhha MH, Karbasi MHA, et al (2018). Evaluation of polymorphism of P53 protein codon 72 in oral lichen planus by PCR technique. J Dent Res Dent Clin Dent Prospects, 12 (4):245-251.
46. Dumont P, Leu JI, Della Pietra AC, et al (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet, 33 (3):357-65.
47. Thomas M, Kalita A, Labrecque S, et al (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol, 19 (2):1092-100.
48. Sobczuk A, Romanowicz-Makowska H, Smolarz B, et al (2007). Microsatellite instability (MSI) and MLH1 and MSH2 protein expression analysis in postmenopausal women with sporadic endometrial cancer. J Exp Clin Cancer Res, 26 (3):369-74.
49. Lee S, Elenbaas B, Levine A, et al (1995). p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell, 81 (7):1013-20.
50. Furihata M, Takeuchi T, Matsumoto M, et al (2002). p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract. Clin Cancer Res, 8 (5):1192-5.
51. Ozer E, Yuksel E, Kizildag S, et al (2002). Microsatellite instability in early-onset breast cancer. Pathol Res Pract, 198 (8):525-30.
52. Stoler DL, Datta RV, Charles MA, et al (2002). Genomic instability measurement in the diagnosis of thyroid neoplasms. Head Neck, 24 (3):290-5.
53. Burger M, Burger SJ, Denzinger S, et al (2006). Elevated microsatellite instability at selected tetranucleotide repeats does not correlate with clinicopathologic features of bladder cancer. Eur Urol, 50 (4):770-5.
54. Saetta AA, Gigelou F, Papanastasiou PI, et al (2006). High-level microsatellite instability is not involved in gallbladder carcinogenesis. Exp Mol Pathol, 80 (1):67-71.
55. Roa JC, Roa I, Melo A, et al (2000). [p53 gene mutation in cancer of the colon and rectum]. Rev Med Chil, 128 (9):996-1004.
56. Leahy DT, Salman R, Mulcahy H, et al (1996). Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis. J Pathol, 180 (4):364-70.
57. Yamashita K, Yoshida T, Shinoda H, et al (2001). Novel method for simultaneous analysis of p53 and K-ras mutations and p53 protein expression in single histologic sections. Arch Pathol Lab Med, 125 (3):347-52.
58. Pan ZZ, Wan DS, Chen G, et al (2004). Co-mutation of p53, K-ras genes and accumulation of p53 protein and its correlation to clinicopathological features in rectal cancer. World J Gastroenterol, 10 (24):3688-90.
59. Iniesta P, Vega FJ, Caldés T, et al (1998). p53 exon 7 mutations as a predictor of poor prognosis in patients with colorectal cancer. Cancer Lett, 130 (1-2):153-60.
60. Cristi E, Perrone G, Toscano G, et al (2005). Tumour proliferation, angiogenesis, and ploidy status in human colon cancer. J Clin Pathol, 58 (11):1170-4.
61. Perrone G, Vincenzi B, Santini D, et al (2004). Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinico-pathological features in colon cancer. Cancer Lett, 208 (2):227-234.
62. Angelopoulou K, Levesque MA, Katsaros D, et al (1998). Exon 5 of the p53 gene is a target for deletions in ovarian cancer. Clin Chem, 44 (1):72-7.
63. Tseng JE, Rodriguez M, Ro J, Liu D, et al (1999). Gender differences in p53 mutational status in small cell lung cancer. Cancer Res, 59 (22):5666-70.
64. Baumbusch LO, Myhre S, Langerød A, et al (2006). Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters. Mol Cancer, 5:47.
65. Webley KM, Shorthouse AJ, Royds JA (2000). Effect of mutation and conformation on the function of p53 in colorectal cancer. J Pathol, 191 (4):361-7.
66. Soussi T, Béroud C (2003). Significance of TP53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides. Hum Mutat, 21 (3):192-200.
67. Olivier M, Hussain SP, Caron de Fromentel C, et al (2004). TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ, (157):247-70.
68. Chang SC, Lin JK, Yang SH, et al (2006). Relationship between genetic alterations and prognosis in sporadic colorectal cancer. Int J Cancer, 118 (7):1721-7.
69. Molleví DG, Serrano T, Ginestà MM, et al (2007). Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection. Carcinogenesis, 28 (6):1241-6.
70. Lim SC, Lee TB, Choi CH, et al (2008). Prognostic significance of cyclooxygenase-2 expression and nuclear p53 accumulation in patients with colorectal cancer. J Surg Oncol, 97 (1):51-6.
71. Theodoropoulos GE, Karafoka E, Papailiou JG, et al (2009). P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up. Anticancer Res, 29 (2):785-91.
72. Eguchi S, Kohara N, Komuta K, et al (1996). Mutations of the p53 gene in the stool of patients with resectable colorectal cancer. Cancer, 77 (8 Suppl):1707-10.
73. Goshayeshi L, Pourahmadi A, Ghayour-Mobarhan M, et al (2019). Colorectal cancer risk factors in north-eastern Iran: A retrospective cross-sectional study based on geographical information systems, spatial autocorrelation and regression analysis. Geospat Health, 14 (2): 10.4081/gh.2019.793.
| Files | ||
| Issue | Vol 54 No 2 (2025) | |
| Section | Review Article(s) | |
| Keywords | ||
| Colorectal cancer P53 mutation Systematic review | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Nikbin Kavishahi N, Yaghmoorian Khojini J, Khamespanah Duruh M, Babaei B, Sheikhha MH. Association between P53 Gene Mutations and Colorectal Cancer in the Iranian Population: A Systematic Review. Iran J Public Health. 2025;54(2):309-320.
